Compare CRS & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRS | DGX |
|---|---|---|
| Founded | 1910 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8B | 25.9B |
| IPO Year | 1994 | 1996 |
| Metric | CRS | DGX |
|---|---|---|
| Price | $296.57 | $245.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 17 |
| Target Price | ★ $438.00 | $257.27 |
| AVG Volume (30 Days) | ★ 1.1M | 834.7K |
| Earning Date | 10-22-2026 | 10-22-2026 |
| Dividend Yield | 0.28% | ★ 1.37% |
| EPS Growth | ★ 41.78 | 13.78 |
| EPS | 3.25 | ★ 7.86 |
| Revenue | $2,157,700,000.00 | ★ $11,035,000,000.00 |
| Revenue This Year | $10.00 | $9.51 |
| Revenue Next Year | $10.17 | $4.45 |
| P/E Ratio | $89.56 | ★ $31.93 |
| Revenue Growth | ★ 20.03 | 11.78 |
| 52 Week Low | $273.45 | $171.18 |
| 52 Week High | $625.99 | $256.99 |
| Indicator | CRS | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 29.25 | 63.96 |
| Support Level | $278.80 | $227.47 |
| Resistance Level | $405.16 | N/A |
| Average True Range (ATR) | 18.03 | 6.75 |
| MACD | -2.18 | 1.53 |
| Stochastic Oscillator | 18.59 | 78.23 |
Carpenter Technology Corp supplies specialty metals to a variety of end markets, including aerospace and defense, industrial machinery and consumer durables, medical, and energy, among others. The company's reportable segments include; Specialty Alloys Operations and Performance Engineered Products. It generates maximum revenue from the Specialty Alloys Operations segment. The SAO segment is comprised of the company's alloy and stainless steel manufacturing operations. This includes operations performed at mills predominantly in Reading and Latrobe, Pennsylvania, and surrounding areas as well as South Carolina and Alabama. Geographically, the company derives its maximum revenue from the United States and the rest from Europe, Asia Pacific, Mexico, Canada, and other regions.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.